What is Cicada COVID? Is it in Arizona yet? All about variant BA.3.2

Variant BA.3.2, nicknamed 'Cicada', has been detected in 25 U.S. states and may evade immunity from vaccines and prior infection. Arizona has no confirmed detections yet, according to David Engelthaler of Arizona State University's Health Observatory, who cautioned there is no evidence but did not rule out its presence.

Analysis

Winners will be firms that own the surveillance-to-manufacturing stack: sequencing platforms, high-volume PCR/assay makers, reagent suppliers and contract biologics manufacturers. An incremental surveillance/mutation wave could lift consumables and sequencing instrument revenues by a visible amount in 1–3 quarters; think 5–15% revenue bump for leaders (Illumina, Thermo Fisher, major diagnostics labs) driven by increased clinical testing, genomic surveillance contracts and CMO fill-and-finish demand.

Therapeutics bifurcate: protease-inhibitor antivirals and broad-spectrum small molecules have asymmetric optionality (limited immunologic dependence) versus narrowly targeted monoclonal antibodies, which face obsolescence risk if neutralization is meaningfully reduced. That creates a multi-month window where demand shifts from monoclonal supply chains (formulation, cold chain, infusion capacity) to outpatient oral antiviral supply and outpatient clinical management capacity.

Key catalysts and tail risks are timing and the immunologic profile: neutralization assays and real-world hospitalization metrics will show directionality in 4–12 weeks once enhanced sequencing and clinical linkage scale up. Reversals are fast — if T-cell cross-protection holds or the variant lacks transmission advantage, market moves can unwind within the same 4–12 week window, and regulatory guidance on updated boosters can either amplify or mute commercial impacts in 2–3 months. The sensible tactical posture is to buy optionality in surveillance and broad-spectrum therapeutics while hedging for the high-probability scenario that severe-disease rates do not rise proportionally to case counts.

Key Decisions for Investors

• Long Illumina (ILMN) or Thermo Fisher (TMO) 3–6 month call spreads (buy ATM, sell OTM) — entry now to capture potential 20–50% upside from stepped-up sequencing contracts and reagent demand; max loss = premium paid, upside capped but capital-efficient if surveillance ramps.
• Long Quest Diagnostics (DGX) or LabCorp (LH) 3–6 month calls — expect increased test volumes and higher-margin molecular testing; target +25–40% upside on sustained test surge, cut if weekly test volumes revert to baseline for 2 consecutive weeks.
• Pair trade: long diagnostics/sequencing basket (ILMN + DGX) vs short discretionary travel/airlines (AAL) for 1–3 months — asymmetric: diagnostics capture immediate revenue, travel downside limited to near-term booking softness; size pair to keep portfolio delta near neutral and use options to cap tail risk.
• Avoid/hedge pure-play monoclonal antibody developers — buy puts on small-cap mAb names or buy protection on names with concentrated mAb exposure (consider buying a 3–6 month put on REGN-sized position) because efficacy loss can wipe valuation rapidly; reward-to-risk favors owning broad-spectrum antivirals and surveillance exposure instead.